

# Vaccine effectiveness against influenza hospitalisation in adults during the 2022/23 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

Angela Rose<sup>1</sup>, Francisco Pozo<sup>2</sup>, Iván Martínez-Baz<sup>3</sup>, Clara Mazagatos<sup>4</sup>, Nathalie Bossuyt<sup>5</sup>, John Paul Cauchi<sup>6</sup>, Goranka Petrovic<sup>7</sup>, Isabela Loghin<sup>8</sup>, Roberta Vaikutyte<sup>9</sup>, Silke Buda<sup>10</sup>, Ausenda Machado<sup>11</sup>, Roisin Duffy<sup>12</sup>, Beatrix Oroszi<sup>13</sup>, Jennifer Howard<sup>14</sup>, Aitziber Echeverria<sup>15</sup>, Cristina Salete<sup>16</sup>, Cyril Barbezange<sup>5</sup>, Ausra Dziugyte<sup>17</sup>, Diana Nonkovic<sup>18</sup>, Corneliu Popescu<sup>19</sup>, Fausta Majauskaite<sup>9</sup>, Kristin Tolksdorf<sup>20</sup>, Verónica Gómez<sup>21</sup>, Lisa Domegan<sup>12</sup>, Judit Horvath<sup>13</sup>, Jesus Castilla<sup>22</sup>, Miriam García-Vázquez<sup>23</sup>, Thomas Demuyser<sup>24</sup>, Maria-Louise Borg<sup>17</sup>, Irena Tabain<sup>7</sup>, Mihaela Lazar<sup>25</sup>, Ieva Kubiliute<sup>26</sup>, Ralf Dürrwald<sup>27</sup>, Raquel Guiomar<sup>28</sup>, Joan O Donnell<sup>12</sup>, Katalin Krisztalovics<sup>13</sup>, Nathalie Nicolay<sup>29</sup>, Sabrina Bacci<sup>29</sup>, and Esther Kissling<sup>1</sup>

<sup>1</sup>Epicontact

<sup>2</sup>Instituto de Salud Carlos III

<sup>3</sup>Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP

<sup>4</sup>Carlos III Health Institute

<sup>5</sup>Sciensano

<sup>6</sup>Ministry of Health Malta

<sup>7</sup>Croatian Institute of Public Health

<sup>8</sup>St Parascheva Clinical Hospital of Infectious Diseases

<sup>9</sup>Lithuanian University of Health Sciences

<sup>10</sup>Robert Koch-Institute

<sup>11</sup>Instituto Nacional de Saude Doutor Ricardo Jorge

<sup>12</sup>Health Service Executive-Health Protection Surveillance Centre

<sup>13</sup>Semmelweis University

<sup>14</sup>Epicentre

<sup>15</sup>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)

<sup>16</sup>Servicio Extremeño de Salud

<sup>17</sup>Malta Health Promotion and Disease Prevention Directorate

<sup>18</sup>Teaching Public Health Institute of Split-Dalmatia County

<sup>19</sup>Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases

<sup>20</sup>Robert Koch Institute

<sup>21</sup>Instituto Nacional de Saude Doutor Ricardo Jorge IP

<sup>22</sup>Instituto de Salud Pública y Laboral de Navarra

<sup>23</sup>Dirección General de Salud Pública, Departamento de Sanidad, Gobierno de Aragón

<sup>24</sup>Universitair Ziekenhuis Brussel

<sup>25</sup>”Cantacuzino” National Military Medical Institute for Research and Development

<sup>26</sup>Vilnius University Institute of Experimental and Clinical Medicine

<sup>27</sup>Robert Koch Institut

<sup>28</sup>Instituto Nacional de Saúde, Dr Ricardo Jorge

<sup>29</sup>European Centre for Disease Prevention and Control

October 10, 2023

## Abstract

We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/23 influenza season in Europe. Among 5547 SARI patients [?18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95%CI: -23–36); 20% (95%CI: -4–39) against A(H3N2) and 56% (95%CI: 22–75) against B. During the 2022/23 season, while VE against hospitalisation with influenza B was >55%, it was [?]20% for influenza A subtypes. While influenza vaccination should be a priority for the upcoming season, improved vaccines against influenza are needed.

## Hosted file

VEBIS 2022-23 flu VE text+title\_v05.docx available at <https://authorea.com/users/672963/articles/671854-vaccine-effectiveness-against-influenza-hospitalisation-in-adults-during-the-2022-23-mixed-season-of-influenza-a-h1n1-pdm09-a-h3n2-and-b-circulation-europe-vebis-sari-ve-hospital-network>

## Hosted file

VEBIS 2022-23 Table 1 ONLY\_v05.docx available at <https://authorea.com/users/672963/articles/671854-vaccine-effectiveness-against-influenza-hospitalisation-in-adults-during-the-2022-23-mixed-season-of-influenza-a-h1n1-pdm09-a-h3n2-and-b-circulation-europe-vebis-sari-ve-hospital-network>

## Hosted file

VEBIS 2022-23 Table 2 ONLY\_v05.docx available at <https://authorea.com/users/672963/articles/671854-vaccine-effectiveness-against-influenza-hospitalisation-in-adults-during-the-2022-23-mixed-season-of-influenza-a-h1n1-pdm09-a-h3n2-and-b-circulation-europe-vebis-sari-ve-hospital-network>

## Hosted file

Figure 1.docx available at <https://authorea.com/users/672963/articles/671854-vaccine-effectiveness-against-influenza-hospitalisation-in-adults-during-the-2022-23-mixed-season-of-influenza-a-h1n1-pdm09-a-h3n2-and-b-circulation-europe-vebis-sari-ve-hospital-network>

## Hosted file

Fig 2 as picture.docx available at <https://authorea.com/users/672963/articles/671854-vaccine-effectiveness-against-influenza-hospitalisation-in-adults-during-the-2022-23-mixed-season-of-influenza-a-h1n1-pdm09-a-h3n2-and-b-circulation-europe-vebis-sari-ve-hospital-network>